IASLC 2025 Preview: Key Lung Cancer Highlights to Watch

IASLC 2025 at a glance

With IASLC 2025 on the horizon, LucidQuest’s preview highlights the key areas of focus, including progress in lung cancer science, innovation in clinical practice, and the expanding impact of AI/ML on decision-making and care pathways.

📅 Build your schedule around the topics that interest you.

📥 Download the IASLC 2025_Preview_by_LucidQuest

Dive deeper

Key Topics From IASLC 2025 Scientific Presentations

SCLC — Immuno-CRT & Targeted Cell Therapy 🤝

• ICIs + CRT improve PFS/OS.

• DLL3 CAR-T shows durable PRs; B7-H3 ADCs remain modest.

NSCLC — Periop Precision, ADCs/TKIs, Smart Combos 🎯

• ALK-targeted perioperative therapy and tailored adjuvant care.

• High-response HER2/PD-L1 ADCs and firmonertinib in uncommon EGFR.

• Atezolizumab + bevacizumab delivers solid survival in select subsets.

Screening — Nodule Dynamics & New Modalities 🔍

• Short-interval LDCT safest for ≥200 mm³ nodules.

• Population pilots feasible.

• Breathomics, DNA-methylation, and sPET/CT complement LDCT.

Early / Rare NSCLC — Tailored Periop & RT 🧪

• LCNEC gains PFS with PD-1/PD-L1 + chemo (OS neutral).

• Chemo-free neoadjuvant IO + RT and EGFR-mut IA3 trials aim for higher pCR/EFS.

Surgery / SABR & Targeted Real-World Use 🛠️

• SABR extends systemic-therapy-free survival with low toxicity.

• Lorlatinib and selpercatinib show durable control.

Immunotherapy — Rechallenge & Resistance 🔄

• ICI rechallenge modest; better with PD-L1 ≥ 50%, prior irAEs, low NLR.

• Epigenetic priming and JAK1 + PD-1 combos emerge.

• In unresectable stage III, IO + chemo enables conversions.

Biomarkers & Liquid Biopsy — Faster Precision 🧬

• ctDNA/CSF and MCP-3 guide leptomeningeal care.

• Rapid liquid-biopsy workflows halve TTD.

• Co-mutations shape ICI/TKI response.

Artificial Intelligence and Machine Learning at IASLC 2025

AI in Screening & Triage 🤖

• AI first-reader cuts workload ~70% with comparable safety; sub-cm models flag cancers up to 24 months early.

AI in Segmentation & Surgical Planning 🧠

• nnU-Net / 3D-U-Net reach expert-level contours; workflow recognition and post-op risk models support OR decisions.

AI in Diagnostics & Non-Invasive Tools 🧪

• Deep learning outperforms regression for GGO; breathomics AUC > 0.90; PD-L1 inferred from H&E correlates with ICI outcomes.

AI in Prognostics & Population Risk 📈

• ML predicts ICI survival (AUC ~0.72–0.80); liver metastases drive worst outcomes; report-mining accelerates incidental nodule detection.

AI in Ops & Real-World Evidence 📊

• AI aligns with Lung-RADS, trims false positives, and speeds insights (e.g., poor-PS pembrolizumab 5-year survivors identified by TMB/KRAS/BRAF).